When to Introduce Aspirin to Reduce Risks of Preeclampsia?
This study by Roberge et al. (AJOG, 2017) surveyed previously performed randomized control trials (RCTs) to determine at what point during pregnancy aspirin should be introduced to reduce the risk of preeclampsia.
Systematic Review and Meta-Analysis
This study analyzed 45 studies which included 20,909 women. Women received aspirin or a placebo starting at ≤ 16 weeks or > 16 weeks. Women who began taking aspirin ≤ 16 weeks displayed lower risk or preeclampsia and fetal growth restriction than those who began taking aspirin > 16 weeks. They also found that the greater the dose, the greater the decrease in risk.
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan